Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 11/20 | 0.40 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.36 |
| ▸ | FPR1 | P21462 | 1/20 | 0.36 |
| ▸ | RBP4 | P02753 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4026512 | 0.87 | NPC1 (0.41) | KDM2BMC4RNPC1TNFRAB9A | |
| SCHEMBL4025458 | 0.85 | NPC1 (0.36) | KDM2BMC4RNPC1TNFRAB9A | |
| SCHEMBL4779138 | 0.84 | MC4R (0.40) | KDM2BMC4RNPC1TNFRAB9A | |
| SCHEMBL4779145 | 0.84 | MC4R (0.40) | KDM2BMC4RNPC1TNFRAB9A | |
| SCHEMBL4021139 | 0.82 | KDM2B (0.43) | KDM2BMC4RNPC1TNFRAB9A | |
| SCHEMBL4749186 | 0.81 | MC4R (0.40) | KDM2BMC4RNPC1TNFRAB9A | |
| SCHEMBL4751345 | 0.81 | MC4R (0.40) | KDM2BMC4RNPC1TNFRAB9A | |
| SCHEMBL4749188 | 0.81 | MC4R (0.40) | KDM2BMC4RNPC1TNFRAB9A | |
| SCHEMBL4021775 | 0.78 | NPC1 (0.35) | KDM2BMC4RNPC1TNFRAB9A | |
| SCHEMBL4749111 | 0.78 | NPC1 (0.34) | KDM2BMC4RNPC1TNFRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572814-B2 | 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds | CYTOKINETICS, INCORPORATED (US) | 2009-08-11 | — | — | US | disclosed |
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161674-A1 | Certain chemical entities, compositions, and methods | TP53, VHL, RB1 | KDM2B 3090/4885MC4R 3874/4885NPC1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.